Nyxoah (NYXH) Cash from Financing Activities (2021 - 2026)
Nyxoah's (NYXH) quarterly Cash from Financing Activities came in at $468298.3 in Q1 2026, down 39.01% year-on-year from $767875.6 in Q1 2025, and down 98.9% quarter-over-quarter from $42.6 million in Q4 2025.
Nyxoah (NYXH) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Nyxoah's Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $468298.3 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 39.01% year-over-year to $468298.3 in Q1 2026; TTM through Mar 2026 was $44.1 million, a 47.49% decrease from a year earlier, with the FY2025 full-year figure at $44.4 million, down 46.4% from the prior year.
- Cash from Financing Activities eased to $468298.3 in Q1 2026 per NYXH's latest filing, from $42.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $48.2 million in Q2 2024 and bottomed at -$2.2 million in Q2 2025.
- The 5-year median for Cash from Financing Activities is $468298.3 (2026), against an average of $8.5 million.
- Biggest YoY gain for Cash from Financing Activities was 9839.52% in 2023; the steepest drop was 245.75% in 2023.
- Year by year, Cash from Financing Activities stood at -$223434.2 in 2022, then plunged by 245.75% to -$772524.9 in 2023, then soared by 3333.35% to $25.0 million in 2024, then soared by 70.56% to $42.6 million in 2025, then plunged by 98.9% to $468298.3 in 2026.
- Per Business Quant, the three latest NYXH Cash from Financing Activities figures stand at $468298.3 (Q1 2026), $42.6 million (Q4 2025), and $3.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | -133.00 Mn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | -414.00 Mn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | -13.00 Mn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | -255.24 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | -50.00 Mn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | -48.13 Mn |
| 10 | Nyxoah | 56.02 Mn | 103.00 Mn | 4.26 Mn | 468,298.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 468,298.26 |
| Mar 31, 2026 | 468,298.26 |
| Dec 31, 2025 | 42.60 Mn |
| Dec 31, 2025 | 42.60 Mn |
| Sep 30, 2025 | 3.17 Mn |
| Sep 30, 2025 | 3.17 Mn |
| Jun 30, 2025 | -2.19 Mn |
| Jun 30, 2025 | -2.19 Mn |
| Mar 31, 2025 | 767,875.64 |
| Mar 31, 2025 | 767,875.64 |
| Dec 31, 2024 | 24.98 Mn |
| Dec 31, 2024 | 24.98 Mn |
| Sep 30, 2024 | 9.98 Mn |
| Sep 30, 2024 | 9.98 Mn |
| Jun 30, 2024 | 48.17 Mn |
| Jun 30, 2024 | 48.17 Mn |
| Mar 31, 2024 | 274,849.53 |
| Mar 31, 2024 | 274,849.53 |
| Dec 31, 2023 | -772,524.85 |
| Dec 31, 2023 | -772,524.85 |